ANL Stock Summary and Trading Ideas (Adlai Nortye Group Ltd. - American Depositary Shares | NASDAQ:ANL)

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Adlai Nortye Group Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ANL.

As of September 4, 2026, ANL stock price climbed to $15.01 with 307,453 million shares trading.

ANL has a beta of 3.18, meaning it tends to be more sensitive to market movements. ANL has a correlation of 0.05 to the broad based SPY ETF.

ANL has a market cap of $966.61 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that ANL belongs to (by Net Assets): CANC, BBC.

ANL has outperformed the market in the last year with a price return of +752.8% while the SPY ETF gained +19.8%. ANL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +36.5% and +9.6%, respectively, while the SPY returned +2.0% and +0.6%, respectively.

ANL support price is $14.04 and resistance is $15.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANL shares will trade within this expected range on the day.